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1. Introduction
Cardiovascular disease remains the leading cause of death worldwide despite many years of
declining mortality rates in the Western world [1,2]. Myocardial infarction carries a short term
mortality rate of about 7% even with aggressive therapy, and congestive heart failure with
even more distressing 20% one-year mortality [3]. Despite significant advances in therapeutic
modalities and risk-reduction strategies, the substantial burden remains. This continued health
problem has prompted research into new therapeutic strategies including cardiac regenerative
therapy as a new approach for severe cardiac diseases resistant to conventional therapies [4,5].
Acute ischemic injury and chronic cardiomyopathies lead to permanent loss of cardiac tissue,
leading to heart failure. For pathologic situations, cell transplantation is thought to be an ideal
therapeutic method for supplying de novo myocardium [6]. Of the available cell sources for
cardiac cell therapy, stem cells (e.g. pluripotent stem cells, bone-marrow derived stem cells,
skeletal myoblasts and cardiac stem cells) are now being prioritized for basic research and
clinical trials [4,7]. The discoveries of various stem cell populations possessing cardiogenic
potential and the advance of methods to isolate and expand these cells have shaped the notion
of cell-based restorative therapy [8-11]. Despite much knowledge gained through numerous
basic researches, significant challenges for true cardiac regeneration remain, and the field lacks
sufficient results conclusive to support full-scale implementation of such treatments. Further‐
more, results of clinical researches in cardiac stem cell therapy with a relatively small cohort
scale were marginal, thus only showing little clinical advantages so far [12].
Among the stem cell types, pluripotent stem cells (PSCs) [Embryonic stem cells (ESCs) /
induced pluripotent stem cells (iPSCs)] possess great capacity for cardiac regeneration mainly
due to the prominent potential to expand and differentiate into most somatic cell lineages
[13,14]. To date, no human trials using PSCs for cardiac repair have been attempted. Intensive
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translational researches, including the demonstration of effectiveness and safety, are needed
to realize clinical application of PSCs.
Another concern is the actual phenomena which are taking place in the niche of transplanted
site: does cardiac stem cell therapy bring de novo functional myocardium, or some indirect
mechanisms mediate cardiac repair? It is reported that very few of the transplanted tissue stem
cells seem to differentiate into mature cardiovascular cell types, suggesting that transplanted
cells exert indirect paracrine effects by which humoral factors induce or support favorable
processes, including angiogenesis, prevention of apoptosis, and promotion of healing, in the
injured myocardium rather than differentiating into de novo myocardium [4,15]. PSCs might
possess advantages in this context; defined cell populations differentiated from PSCs might
be effective to elucidate underlying paracrine mechanisms in cardiac restoration compared to
bulk cell mixture derived from somatic stem cells with various cell lineages and differentiation
stages [16].
Concerning stem cell transplantation, as well as the transplanted cell type, the method for
transplantation is also important to overcome the poor efficiency of engraftment with needle
injection. A promising approach is the creation of cell sheets that better support effective
engraftment of the transplants. We have shown the effectiveness of temperature-responsive
cell sheet technology in basic studies [16].
In this chapter, we introduce the clarification for the progress and drawbacks of current cardiac
stem cell therapy, and finally indicate the future directions of cardiac cell therapy through our
recent researches combining PSCs and cell sheet technology.
2. Various somatic stem cell populations for cardiac stem cell therapy
To date, various somatic stem cells have been investigated for their feasibility to cardiac
regenerative therapy with many basic studies.
Bone marrow hematopoietic stem cells (or circulating peripheral-blood progenitor cells) are
an abundant and well characterized source of progenitor cells. A number of studies have
shown that direct transplantation of bone marrow-derived cells or mobilization from endog‐
enous reservoirs of the cell population significantly improves cardiac function [17,18].
However, other investigations found limited differentiation of bone marrow cells into
cardiovascular cell types [19]. This suggests that beneficial results were mainly due to indirect
paracrine effects such as neovascularization, independent of direct tissue regeneration.
Mesenchymal stem cells (MSCs) are a subset of stem cells found in the stroma of the bone
marrow, adipose tissue, fetal membrane and many other tissues that can differentiate into
osteoblasts, chondrocytes, and adipocytes [20,21] and also into small numbers of cardiomyo‐
cytes [8]. MSCs are thought to be either less immunogenic than other stem cell populations or
inherently immunomodulatory [22], alleviating the need for immunosuppression prior to
transplantation. Transplantation of MSCs into infarct animal models demonstrated improved
left ventricular function, reduced infarct size, and increased survival rate [8,22,23]. The major
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disadvantage of MSCs for this clinical application is the broad differentiation capacity; MSC
populations remain highly heterogeneous and are less predictable after transplantation. Some
studies have shown that MSCs differentiated into osteoblasts inside ventricular tissue after
transplantation [24].
Endothelial progenitor cells (EPCs) are another promising stem cell subset which accumulate
to vascular injury sites from bone marrow and incorporate into the microvasculature (vascu‐
logenesis) [9]. EPCs can be identified by the ability to acquire the expression of endothelial cell
surface makers, such as cluster of differentiation molecule 133 (CD133), CD34 and so on, both
in vitro and in vivo [25]. The research into their therapeutic use began with attempts to enhance
their mobilization or incorporate EPCs directly into the vasculature of injured sites [26].
Preclinical studies of the injection of EPCs to infarct myocardium improved left ventricular
function [15]. Although EPCs remain promising as a potential therapeutic material, they have
several disadvantages for cell therapy: 1) Their heterogeneity. EPCs circulating in the periph‐
eral blood span the full range of differentiation from angioblasts to mature endothelial cells.
2) Limited stem cell pool. Ex vivo expansion would be the only way to obtain a sufficient
amount of EPCs for the treatment of an ischemic injury [27]. 3) The pool of EPCs is reduced in
patients with common comorbidities of cardiac ischemia (e.g. diabetes mellitus, hypertension,
and hyperlipidemia) [28].
Skeletal myoblasts (SMs) are a stem cell population derived from the satellite cells which exists
beneath the basal membrane of adult skeletal muscle tissue [29]. SMs have been considered as
an attractive source for cardiac restoration because of the small potential for teratoma forma‐
tion, availability for autologous transplantation, resistance to ischemic condition and so on
[10]. Most transplantations in animal disease models improved left ventricular function and
decreased ventricular remodeling [10,30]. There are however, two main limitations; the first
is the arrhythmogenic potential of the engrafted SMs. It is reported that only a fraction of
skeletal myoblasts differentiate into cardiomyocytes after transplantation, and the generated
myotubules may not synchronically work with the native myocardium [31]. A large scale
clinical trial, Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial,
showed a higher number of arrhythmic events in myoblast-treated patients [32]. The second
limitation is the relatively poor engraftment of the transplanted cells into the host myocardium.
It is reported that less than 10% of transplanted cells could survive within the first few days
after injection in mice [33].
Several populations of cardiac progenitor / stem cells derived from mature cardiac tissue have
been reported, which may hold the natural and endogenous cardiac regenerative mechanisms.
Traditionally, the heart has been considered to be a post-mitotic organ, and withdrawn from
the proliferative cell cycle. However, some contradictory data have reported, as cardiomyocyte
proliferation and cell cycling have been observed under pathological conditions (e.g. hyper‐
tension or myocardial infarction) [34, 35] and even in the healthy heart [36]. These evidences
prompted further research for such resident cardiac cells. The first cell population with stem
cell properties is called the side population (SP) cells. Isolated cardiac SP cells represent cardiac
and vascular progenitor cells and can differentiate into cardiomyocytes, endothelial cells, or
smooth muscle cells [37]. The second progenitor population is the cells expressing the stem
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cell factor receptor c-Kit (also designed as CD117), which are located in small clusters within
the adult cardiac tissue. c-Kit+ cells hold regenerative potential after transplantation and give
rise to cardiomyocytes, endothelial cells, and smooth muscle cells [38]. The third cell type
expresses stem cell antigen 1 (Sca-1). Sca-1+ cells migrate to infarcted myocardium and
differentiate into cardiomyocytes around the injured area [39]. Finally, enzymatic digestion of
heart tissue obtained via endomyocardial biopsy or during cardiac surgery yields cardiac
progenitor cells that form what is called cardiospheres. Cardiosphere derived cells (CDCs) can
also differentiate into cardiomyocytes, endothelial cells, and smooth muscle cells, exhibiting
prominent capacities for proliferation and differentiation [11]. This population can be differ‐
entiated into aggregates of cardiomyocytes that when transplanted into injured myocardium
produced functional improvement in preclinical studies [40]. It is unclear whether the various
cardiac stem cells shown here are different populations, or represent various stages of a single
cell lineage. A major limitation of cardiac progenitor / stem cell populations is that the cardiac
stem cell pool appears to diminish along with age, which may limit the efficacy of regeneration
in elderly people [41]. Considering that it is mostly the elderly who suffer increased mortality
from cardiac ischemia, intensive research aiming to rejuvenate this senescent stem cell
population is required.
Many clinical studies have been conducted using these somatic stem cells so far: TOPCARE-
AMI [42], BOOST [43], REPAIR-AMI [44], LateTime [45] (Bone marrow hematopoietic stem
cells), REGENT [46] (EPCs), MAGIC [32], CAuSMIC [47] (SMs), CADUCEUS [48], SCIPIO [49]
(cardiac progenitor / stem cells) and so on. However, most of these clinical studies have shown
relatively limited clinical benefits in general. These marginal results indicate that more efficient
approaches for stem cell therapy are needed to realize full-scale stem cell-based therapy.
3. Advantages of pluripotent stem cells in cardiac regeneration
Embryonic stem cells (ESCs) are one of the stem cell populations which can be removed from
the inner cell mass of the blastocyst and expanded in vitro with practically no limitations [13].
Yamanaka and colleagues have discovered that reprogramming of adult somatic cells with
transcription factor genes that confer pluripotency generates ESC-like cells, called induced
pluripotent stem cells (iPSCs) [14,50]. Among the stem cell types, these pluripotent stem cells
(PSCs) [ESCs / iPSCs] possess great capacity especially for cardiac regeneration due to several
reasons.
The first reason is that PSCs can be expanded practically indefinitely in vitro remaining
pluripotent in an undifferentiated state in culture, and can give rise to most somatic cell
lineages once allowed to differentiate. In this regard, the regenerative capacity is theoretically
limitless [51]. The merit of PSCs is larger especially for the heart compared to other organs,
such as endocrine or sensory organs, as the heart functions as an assembly of a large number
of cells including cardiomyocytes and other cell types (e.g. vascular cells, cardiac fibroblasts),
and numerous (>108) heart-composing cells might be required to fully compensate for the
damaged human heart [5].
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The second reason is that the capacity for the differentiation towards a desired cell type, such
as cardiomyocytes or other vascular cell types is the highest among various stem cell popula‐
tions known to possess cardiogenic potential. The differentiation of PSCs can be driven
towards cardiomyocytes or others by culture conditions as monolayers or embryoid bodies in
various growth media [52–55]. Previously, we have developed a novel monolayer culture-
based ESC / iPSC differentiation system that recapitulates early cardiovascular developmental
processes using Flk1 (also designed as vascular endothelial cell growth factor [VEGF] recep‐
tor-2)-positive cells as common cardiovascular progenitors. Cardiovascular cell types, namely
cardiomyocytes [53], endothelial cells, and vascular mural cells [52], can be systematically
induced and purified with this system (Figure 1A). In fact, of the various stem cell populations
studied so far, PSCs have demonstrated probably the greatest capacity for cardiac cell
differentiation and long-term cell survival [56].
The third reason is that PSCs might be advantageous for further elucidation of regenerative
mechanisms. In the field of cardiac restoration with stem cell therapy, it has been widely
believed that transplanted cells act as an inducer of indirect paracrine effects such as angio‐
genesis, prevention of apoptosis, and so on rather than regeneration of de novo myocardium
[4,15]. Considering this point, the transplantation of somatic stem cells, which are largely
performed thus far as mentioned above, may raise a question, “which cells are really effec‐
tive?”, because the transplanted cells from somatic stem cells might consist of heterogeneous
cell populations. In this regard, the transplantation of defined cardiovascular cell populations
systematically derived from PSCs might be much more superior to that of somatic stem cell-
derived populations for the sake of the elucidation of regenerative mechanisms (Figure 1B).
The final reason is the discovery of iPSCs. The generation of iPSCs by reprogramming
autologous somatic cells with genes regulating pluripotency may resolve the ethical and
immunogenic issues associated with the use of ESCs. Furthermore, we have reported that
cardiovascular cell types can be differentiated respectively from mouse iPSCs almost identi‐
cally with those from mouse ESCs [57]. This indicates that iPSCs possess almost the same
regenerative capacity as that of ESCs. A potent differentiation protocol based on high-density
monolayer culture and chemically defined factors, and modifications thereof, have been
reported to induce cardiomyocytes from human iPSCs with a robust efficiency of 40–70 % [54,
58]. The application of this method would strongly promote cardiac regeneration using human
iPSCs.
The transplantation of cardiac cells derived from PSCs has been tested in animal studies with
encouraging results [16, 54]. However, no human studies using PSCs for cardiac repair have
been attempted so far. A major concern regarding iPSC transplantation as a treatment modality
is related to the potential tumor formation. The differentiating cells from PSCs contain
derivatives from three germ layers (ectoderm, mesoderm and endoderm), possessing the
capacity to differentiate along any or all of these three lineages. This increases the risk of
teratoma formation at the transplantation site. Although such teratomas are believed to be
largely benign, some teratoma cells have been reported to express markers similar to those
seen in malignant tumors [59]. Recently, protocols for generating human iPSCs without
genomic integration by utilizing episomal vectors [60] or human artificial chromosome vectors
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Figure 1. The advantages of PSCs for cardiac regeneration. (A): The capacity for the differentiation towards a desired
cardiac cell type. The scheme of directed mouse PSC differentiation system from Flk1+ mesoderm cells as a common
progenitor is shown. (B): Effectiveness for further elucidation of regenerative mechanisms. The usage of somatic stem
cells (upper) may lead to the transplantation of heterogeneous derivatives in lineage and differentiation stage. On the
other hand, the usage of directed PSC differentiation system with purifying processes (lower) clarify which cell popula‐
tions are actually transplanted. ES cell, embryonic stem cell; iPS cell, induced pluripotent stem cell.
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[61] have been reported. These may reduce tumorigenesis due to mutations, which could
otherwise limit the clinical application of iPSCs.
Considering the results of these basic studies, PSCs (especially iPSCs) are currently recognized
to be one of the most promising cell sources for cardiac regeneration. However, further careful
exploration for the feasibility of this new modality will be needed to realize the clinical
application.
4. Cell sheet technology as a novel method for PSC-derived cell
transplantation
In addition to the transplanted cell type, the transplantation method is also important to
overcome poor efficiency of engraftment associated with needle injection. The low level of
grafted cell survival and engraftment diminishes their potential for paracrine effects, besides
regeneration of de novo myocardium, and is a major technical limitation for stem cell therapy
[62]. It is reported that >70% of injected cells die during the first 48 hours after needle injection,
progressively diminishing during the following days possibly due to the hypoxic, inflamma‐
tory, and/or fibrotic environment [63]. Another report shows that only 5.4 to 8.8% of micro‐
spheres remain just after direct injection into the beating myocardium due to massive
mechanical loss [64]. To overcome this problem, a combination of bioengineering techniques
have been developed and investigated for their efficacy, suggesting that these new strategies
may improve the efficiency of stem cell therapies [65].
Initial experiments were performed by combining the cells with injectable biomaterials such
as collagen, fibrin, gelatin or matrigel as a sccafold. In general, early results showed an
increased survival of the transplanted cells, and a greater improvement in cardiac function of
the treated hearts [66]. However, these approaches did not assure complete cell retention or
an adequate distribution of the transplanted cells within the host heart.
The creation of cell sheets without scaffold support would be a more promising approach. The
advantages of this method are as follows: 1) Potent increase of the efficiency of transplantation
compared to that of needle injection. 2) Potential for construction of three-dimentional tissue-
like structure as a graft. 3) Avoidance of inflammatory reactions against the biomaterials
constituting the scaffolds. 4) Larger scalability and accessibility due to two-dimensional cell
culture.
Several methods have been reported for cell sheet formation [67-69]. Among them, we have
utilized temperature-responsive culture surface-based method [16]. This technique was made
possible by using a culture dish covalently grafted with temperature-responsive polymer poly
(N-isopropylacrylamide) (PIPAAm) which enables the generation of cell sheets without
enzymatic digestion, retaining intact extracellular matrices or adhesion molecules [67]. The
benefits of this technique have been demonstrated by many experiments of stem cell therapy
such as the transplantation of monolayer adipose tissue-derived MSCs to the infarcted rat heart
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Figure 2. The improvement of infarcted heart function after transplantation of cardiac tissue sheets bioengineered
with mouse ES cell-derived defined cardiac cell populations. (A): Cross-sections of the sheet. Upper panel: H&E stain‐
ing showing cell appearance of the sheet. Lower panel: Sirius red staining showing intact extracellular matrix. (B): Im‐
munostaining of sheets for cTnT (red), VE-cadherin (green), and DAPI. (C,D): Echocardiogram (n=9). (C): Representative
M-mode image. Note that infarct anterior wall started to move 2–4 weeks after transplantation (Tx). (D): Fractional
shortening (FS). (E): LV pressure-volume loop study 4 weeks after Tx (n=8). Ees: End-systolic elastance. (F, G): Capillary
formation at Tx-d28. (F): Double staining for vWF (ECs, green) and cTnT (cardiomyocytes [CMs], red) at peri-MI and
central-MI areas. Note that newly formed capillaries are clearly observed in transplantation group (dotted circles). (G):
Quantification of capillary density (capillary number per square millimeter). Peri-MI area (left panel) and central-MI
area (right panel) (15 views each). (H): Triple staining for vWF, cTnT, and species-specific fluorescent in situ hybridiza‐
tion (mouse nuclei, yellow) (Tx-d3). Most of the accumulated vWF-positive cells are negative for mouse nuclear stain‐
ing (arrows). Inset: higher magnification view. **, p <.01; and ***, p <.001 (unpaired t test), †, p <.05 and ‡, p <.01 (vs.
PreTx, paired t test). PreTx; Pretransplantation, Tx2w, Tx4w; 2 and 4 weeks after transplantation, respectively. Scale
bars: 200 μm in (B), 100 μm in (F) and (H) (main panel), 50 μm in (H) (inset). HE, Hematoxylin and Eosin; cTnT, cardiac
troponin-T; DAPI, 4,6-diamidino-2-phenylindole; vWF, von Willebrandfactor.; MI, myocardial infarction. (quote from
ref. 16 with revision)
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Figure 3.  Cell  type-controlled sheet  analyses.  (A):  The Scheme of  cell  sheets  with CMs (C+E+M) or  without  CMs
(E+M).  (B):  ELISA  for  VEGF  secretion  (picogram  per104  cells)  in  culture  supernatants  of  C+E+M  and  E+M  sheets.
(C,D):  Transplantation of sham operation (n=9) versus C+E+M sheets (n=9) versus E+M sheets (n=3) (Tx-d28).  (C):
Capillary density in peri-MI area (capillary number per square millimeter).  (15 views each). (D): Fractional shorten‐
ing (FS) on echocardiogram (fold increase vs.  PreTx).  **,  p <.01, and ***,  p <.001 (unpaired t test).  C:  cardiomyo‐
cytes,  E:  endothelial  cells,  M:  vascular  mural  cells.  N.S.,  not  significant;  VEGF,  vascular  endothelial  cell  growth
factor. (quote from ref. 16 with revision).
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[23]. Recently, we have reported transplantation of a three-layered cardiac tissue sheet
bioengineered with mouse ESC-derived defined cardiac cell populations in the infarcted heart
(Figure 2) [16]. In both cases, increased tissue neovascularization together with a prominent
attenuation of cardiac remodeling responsible for the improvement in cardiac function were
demonstrated. Furthermore, our research indicated the potential for cell sheet-based prospec‐
tive elucidation of the cellular mechanisms of cardiac restoration. The combinations of cell
populations composing the transplanted cell sheets enabled us to elucidate the contributions
of each cell type (for example, the comparison of cell sheets with or without cardiomyocytes
is useful for the elucidation of the cellular function of cardiomyocytes). This cell-type control‐
led analysis led us to identify one of the important cellular mechanisms of cardiac restoration
following cell therapy, that is, cardiomyocytes are essential for the functional improvement of
ischemic heart through neovascularization (Figure 3). These results show that the tissue-like
cell sheet system is advantageous for the elucidation of cardiac regenerative mechanism, as
well as for therapeutic purposes.
5. Future directions
One future direction of this PSC-derived cell sheet technology is its utilization as a novel
experimental tool for elucidation of regenerative mechanisms. Although the present results of
clinical trials using stem cell therapy are marginal, further elucidation of the actual mechanisms
of cardiac repair following cell therapy would enhance the potential of stem cell therapy to be
a full-scale therapy. It would be a breakthrough for further improvement of cardiac cell therapy
to understand the role of each cell population as well as the various cellular interactions in the
chaos of heterogeneity.
Another direction is a more efficient survival of transplanted sheets to realize regeneration of
functioning de novo myocardium. Considering that more cells that survived were observed in
peri-infarction than central infarction region in our study [16], it would be possible that the
severe ischemic condition may not be suitable for sheet survival. Novel techniques increasing
blood supply in the graft should be applied, such as prevascularization in 3-dimensional tissue
formation [70,71] or vascularized flap grafts.
6. Conclusion
In this chapter, we have reviewed the status quo of current cardiac stem cell therapy, and
shown the promising potential of PSC-derived cardiac tissue-like sheets. The knowledge
yielded from this cell sheet-based study would provide a hallmark for cell therapy with PSCs
and a strategic principle for future cardiac restoration therapy.
Pluripotent Stem Cells468
Author details
Hidetoshi Masumoto1,2* and Jun K. Yamashita1
*Address all correspondence to: masumoto@kuhp.kyoto-u.ac.jp
1 Laboratory of Stem Cell Differentiation, Department of Cell Growth and Differentiation,
Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
2 Department of Cardiovascular Surgery, Kyoto University Graduate School of Medicine,
Kyoto, Japan
References
[1] World Health Organization (WHO)The global burden of disease: 2004 update. 2008.
http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/
index.html accessed 31 August (2012).
[2] Ford, E. S, & Capewell, S. (2011). Proportion of the Decline in Cardiovascular Mortal‐
ity Disease due to Prevention Versus Treatment: Public Health Versus Clinical Care.
Annu Rev Public Health , 32, 5-22.
[3] Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3
Investigators(2001). Efficacy and safety of tenecteplase in combination with enoxa‐
parin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute
myocardial infarction. Lancet , 358, 605-613.
[4] Joggerst, S. J, & Hatzopoulos, A. K. (2009). Stem cell therapy for cardiac repair: bene‐
fits and barriers. Expert Rev Mol Med 11,e20.
[5] Masumoto, H, & Sakata, R. Cardiovascular surgery for realization of regenerative
medicine. Gen Thorac Cardiovasc Surg. In press.
[6] Sakakibara, Y, Tambara, K, Lu, F, Nishina, T, Sakaguchi, G, Nagaya, N, Nishimura,
K, Li, R. K, Weisel, R. D, & Komeda, M. (2002). Combined procedure of surgical re‐
pair and cell transplantation for left ventricular aneurysm: an experimental study.
Circulation 106,II197., 193.
[7] Chien, K. R. (2008). Regenerative medicine and human models of human disease.
Nature , 453, 302-305.
[8] Tomita, S, Li, R. K, Weisel, R. D, Mickle, D. A, Kim, E. J, Sakai, T, & Jia, Z. Q. (1999).
Autologous transplantation of bone marrow cells improves damaged heart function.
Circulation 100,IIII256., 247.
Pluripotent Stem Cells for Cardiac Cell Therapy: The Application of Cell Sheet Technology
http://dx.doi.org/10.5772/56326
469
[9] Asahara, T, Murohara, T, Sullivan, A, Silver, M, Van Der Zee, R, Li, T, Witzenbichler,
B, Schatteman, G, & Isner, J. M. (1997). Isolation of putative progenitor endothelial
cells for angiogenesis. Science , 275, 964-967.
[10] Murry, C. E, Wiseman, R. W, Schwartz, S. M, & Hauschka, S. D. (1996). Skeletal myo‐
blast transplantation for repair of myocardial necrosis. J Clin Invest , 98, 2512-2523.
[11] Messina, E, De Angelis, L, Frati, G, Morrone, S, Chimenti, S, Fiordaliso, F, Salio, M,
Battaglia, M, Latronico, M. V, Coletta, M, et al. (2004). Isolation and expansion of
adult cardiac stem cells from human and murine heart. Circ Res , 95, 911-921.
[12] Rosenzweig, A. (2006). Cardiac cell therapy--mixed results from mixed cells. N Engl J
Med , 355, 1274-1277.
[13] Thomson, J. A, Itskovitz-eldor, J, Shapiro, S. S, Waknitz, M. A, Swiergiel, J. J, Mar‐
shall, V. S, & Jones, J. M. (1998). Embryonic stem cell lines derived from human blas‐
tocysts. Science , 282, 1145-1147.
[14] Takahashi, K, Tanabe, K, Ohnuki, M, Narita, M, Ichisaka, T, Tomoda, K, & Yamana‐
ka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by de‐
fined factors. Cell , 131, 861-872.
[15] Kocher, A. A, Schuster, M. D, Szabolcs, M. J, Takuma, S, Burkhoff, D, Wang, J, Hom‐
ma, S, Edwards, N. M, & Itescu, S. (2001). Neovascularization of ischemic myocardi‐
um by human bone-marrow derived angioblasts prevents cardiomyocyte apoptosis,
reduces remodeling and improves cardiac function. Nat Med , 7, 430-436.
[16] Masumoto, H, Matsuo, T, Yamamizu, K, Uosaki, H, Narazaki, G, Katayama, S, Mar‐
ui, A, Shimizu, T, Ikeda, T, Okano, T, et al. (2012). Pluripotent stem cell-engineered
cell sheets reassembled with defined cardiovascular populations ameliorate reduc‐
tion in infarct heart function through cardiomyocyte-mediated neovascularization.
Stem Cells , 30, 1196-1205.
[17] Orlic, D, Kajstura, J, Chimenti, S, Jakoniuk, I, Anderson, S. M, Li, B, Pickel, J, Mckay,
R, Nadal-ginard, B, Bodine, D. M, et al. (2001). Bone marrow cells regenerate infarct‐
ed myocardium. Nature , 410, 701-705.
[18] Orlic, D, Kajstura, J, Chimenti, S, Limana, F, Jakoniuk, I, Quaini, F, Nadal-ginard, B,
Bodine, D. M, Leri, A, & Anversa, P. (2001). Mobilized bone marrow cells repair the
infarcted heart, improving function and survival. Proc Natl Acad Sci USA. , 98,
10344-10349.
[19] Murry, C. E, Soonpaa, M. H, Reinecke, H, Nakajima, H, Nakajima, H. O, Rubart, M,
Pasumarthi, K. B, Virag, J. I, Bartelmez, S. H, Poppa, V, et al. (2004). Haematopoietic
stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Na‐
ture , 428, 664-668.
Pluripotent Stem Cells470
[20] Jiang, Y, Jahagirdar, B. N, Reinhardt, R. L, Schwartz, R. E, Keene, C. D, Ortiz-gonza‐
lez, X. R, Reyes, M, Lenvik, T, Lund, T, Blackstad, M, et al. (2002). Pluripotency of
mesenchymal stem cells derived from adult marrow. Nature , 418, 41-49.
[21] Ishikane, S, Yamahara, K, Sada, M, Harada, K, Kodama, M, Ishibashi-ueda, H, Haya‐
kawa, K, Mishima, K, Iwasaki, K, Fujiwara, M, et al. (2010). Allogeneic administra‐
tion of fetal membrane-derived mesenchymal stem cells attenuates acute myocarditis
in rats. J Mol Cell Cardiol. , 49, 753-761.
[22] Dai, W, Hale, S. L, Martin, B. J, Kuang, J. Q, Dow, J. S, Wold, L. E, & Kloner, R. A.
(2005). Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myo‐
cardium: short- and long-term effects. Circulation , 112, 214-223.
[23] Miyahara, Y, Nagaya, N, Kataoka, M, Yanagawa, B, Tanaka, K, Hao, H, Ishino, K,
Ishida, H, Shimizu, T, Kangawa, K, et al. (2006). Monolayered mesenchymal stem
cells repair scarred myocardium after myocardial infarction. Nat Med , 12, 459-465.
[24] Yoon, Y. S, Park, J. S, Tkebuchava, T, Luedeman, C, & Losordo, D. W. (2004). Unex‐
pected severe calcification after transplantation of bone marrow cells in acute myo‐
cardial infarction. Circulation , 109, 3154-3157.
[25] Hristov, M, & Weber, C. (2008). Endothelial progenitor cells in vascular repair and
remodeling. Pharmacol Res , 58, 148-151.
[26] Llevadot, J, Murasawa, S, Kureishi, Y, Uchida, S, Masuda, H, Kawamoto, A, Walsh,
K, Isner, J. M, & Asahara, T. (2001). HMG-CoA reductase inhibitor mobilizes bone
marrow-derived endothelial progenitor cells. J Clin Invest , 108, 399-405.
[27] Jujo, K, Ii, M, & Losordo, D. W. (2008). Endothelial progenitor cells in neovasculariza‐
tion of infarcted myocardium. J Mol Cell Cardiol , 45, 530-544.
[28] Vasa, M, Fichtlscherer, S, Aicher, A, Adler, K, Urbich, C, Martin, H, Zeiher, A. M, &
Dimmeler, S. (2001). Number and migratory activity of circulating endothelial pro‐
genitor cells inversely correlate with risk factors for coronary artery disease. Circ Res
89,EE7., 1.
[29] Buckingham, M, & Montarras, D. Skeletal muscle stem cells. ((2008). Curr Opin Gen‐
et Dev. , 18, 330-336.
[30] Taylor, D. A, Atkins, B. Z, Hungspreugs, P, Jones, T. R, Reedy, M. C, Hutcheson, K.
A, Glower, D. D, & Kraus, W. E. (1998). Regenerating functional myocardium: im‐
proved performance after skeletal myoblast transplantation. Nat Med , 4, 929-933.
[31] Farahmand, P, Lai, T. Y, Weisel, R. D, Fazel, S, Yau, T, Menasche, P, & Li, R. K.
(2008). Skeletal myoblasts preserve remote matrix architecture and global function
when implanted early or late after coronary ligation into infarcted or remote myocar‐
dium. Circulation 118,SS137., 130.
[32] Menasche, P, Alfieri, O, Janssens, S, Mckenna, W, Reichenspurner, H, Trinquart, L,
Vilquin, J. T, Marolleau, J. P, Seymour, B, Larghero, J, et al. (2008). The Myoblast Au‐
Pluripotent Stem Cells for Cardiac Cell Therapy: The Application of Cell Sheet Technology
http://dx.doi.org/10.5772/56326
471
tologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized pla‐
cebo-controlled study of myoblast transplantation. Circulation , 117, 1189-1200.
[33] Suzuki, K, Murtuza, B, Beauchamp, J. R, Smolenski, R. T, Varela-carver, A, Fukushi‐
ma, S, Coppen, S. R, Partridge, T. A, & Yacoub, M. H. (2004). Dynamics and media‐
tors of acute graft attrition after myoblast transplantation to the heart. FASEB J , 18,
1153-1155.
[34] Anversa, P, Palackal, T, Sonnenblick, E. H, Olivetti, G, & Capasso, J. M. (1990). Hy‐
pertensive cardiomyopathy. Myocyte nuclei hyperplasia in the mammalian rat heart.
J Clin Invest , 85, 994-997.
[35] Beltrami, A. P, Urbanek, K, Kajstura, J, Yan, S. M, Finato, N, Bussani, R, Nadal-gi‐
nard, B, Silvestri, F, Leri, A, Beltrami, C. A, et al. (2001). Evidence that human cardiac
myocytes divide after myocardial infarction. N Engl J Med , 344, 1750-1757.
[36] Bergmann, O, Bhardwaj, R. D, Bernard, S, & Zdunek, S. Barnabe´-Heider F, Walsh S,
Zupicich J, Alkass K, Buchholz BA, Druid H et al. ((2009). Evidence for cardiomyo‐
cyte renewal in humans. Science , 324, 98-102.
[37] Oyama, T, Nagai, T, Wada, H, Naito, A. T, Matsuura, K, Iwanaga, K, Takahashi, T,
Goto, M, Mikami, Y, Yasuda, N, et al. (2007). Cardiac side population cells have a po‐
tential to migrate and differentiate into cardiomyocytes in vitro and in vivo. J Cell Bi‐
ol , 176, 329-341.
[38] Beltrami, A. P, Barlucchi, L, Torella, D, Baker, M, Limana, F, Chimenti, S, Kasahara,
H, Rota, M, Musso, E, Urbanek, K, et al. (2003). Adult cardiac stem cells are multipo‐
tent and support myocardial regeneration. Cell , 114, 763-776.
[39] Oh, H, Bradfute, S. B, Gallardo, T. D, Nakamura, T, Gaussin, V, Mishina, Y, Pocius, J,
Michael, L. H, Behringer, R. R, Garry, D. J, et al. (2003). Cardiac progenitor cells from
adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl
Acad Sci USA , 100, 12313-12318.
[40] Takehara, N, Tsutsumi, Y, Tateishi, K, Ogata, T, Tanaka, H, Ueyama, T, Takahashi, T,
Takamatsu, T, Fukushima, M, Komeda, M, et al. (2008). Controlled delivery of basic
fibroblast growth factor promotes human cardiosphere-derived cell engraftment to
enhance cardiac repair for chronic myocardial infarction. J Am Coll Cardiol , 52,
1858-65.
[41] Torella, D, & Ellison, G. M. Me´ndez-Ferrer S, Ibanez B and Nadal-Ginard B. ((2006).
Resident human cardiac stem cells: role in cardiac cellular homeostasis and potential
for myocardial regeneration. Nat Clin Pract Cardiovasc Med 3,SS13., 8.
[42] Leistner, D. M, Fischer-rasokat, U, Honold, J, & Seeger, F. H. Scha°chinger V, Leh‐
mann R, Martin H, Burck I, Urbich C, Dimmeler S et al. ((2011). Transplantation of
progenitor cells and regeneration enhancement in acute myocardial infarction (TOP‐
Pluripotent Stem Cells472
CARE-AMI): final 5-year results suggest longterm safety and efficacy. Clin Res Car‐
diol , 100, 925-934.
[43] Meyer, G. P, Wollert, K. C, Lotz, J, Steffens, J, Lippolt, P, Fichtner, S, Hecker, H,
Schaefer, A, Arseniev, L, Hertenstein, B, et al. (2006). Intracoronary bone marrow cell
transfer after myocardial infarction: eighteen months’ follow-up data from the
randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation in‐
farct regeneration) trial. Circulation , 113, 1287-1294.
[44] Assmus, B, Rolf, A, & Erbs, S. Elsa°sser A, Haberbosch W, Hambrecht R, Tillmanns
H, Yu J, Corti R, Mathey DG et al. ((2010). Clinical outcome 2 years after intracorona‐
ry administration of bone marrow-derived progenitor cells in acute myocardial in‐
farction. Circ Heart Fail , 3, 89-96.
[45] Traverse, J. H, Henry, T. D, Ellis, S. G, Pepine, C. J, Willerson, J. T, Zhao, D. X, Forder,
J. R, Byrne, B. J, Hatzopoulos, A. K, Penn, M. S, et al. (2011). Effect of intracoronary
delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute
myocardial infarction on left ventricular function: the LateTIME randomized trial.
JAMA , 306, 2110-2119.
[46] Tendera, M, Wojakowski, W, Ruzyllo, W, Chojnowska, L, Kepka, C, Tracz, W, Musi‐
alek, P, Piwowarska, W, Nessler, J, Buszman, P, et al. (2009). Intracoronary infusion
of bone marrowderived selected CD34+CXCR4+ cells and non-selected mononuclear
cells in patients with acute STEMI and reduced left ventricular ejection fraction: re‐
sults of randomized, multicenter Myocardial Regeneration by Intracoronary Infusion
of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial.
Eur Heart J , 30, 1313-1321.
[47] Dib, N, Dinsmore, J, Lababidi, Z, White, B, Moravec, S, Campbell, A, Rosenbaum, A,
Seyedmadani, K, Jaber, W. A, Rizenhour, C. S, et al. (2009). One-year follow-up of
feasibility and safety of the first US, randomized, controlled study using 3-dimen‐
sional guided catheter-based delivery of autologous skeletal myoblasts for ischemic
cardiomyopathy (CAuSMIC study). JACC Cardiovasc Interv , 2, 9-16.
[48] Makkar, R. R, Smith, R. R, Cheng, K, Malliaras, K, Thomson, L. E, Berman, D, Czer,
L. S, Marbán, L, Mendizabal, A, Johnston, P. V, et al. (2012). Intracoronary cardio‐
sphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS):
a prospective, randomised phase 1 trial. Lancet , 379, 895-904.
[49] Bolli, R, Chugh, A. R, Amario, D, Loughran, D, Stoddard, J. H, Ikram, M. F, Beache,
S, Wagner, G. M, Leri, S. G, & Hosoda, A. T et al. ((2011). Cardiac stem cells in pa‐
tients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase
1 trial. Lancet , 378, 1847-1857.
[50] Takahashi, K, & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse
embryonic and adult fibroblast cultures by defined factors. Cell , 126, 663-676.
Pluripotent Stem Cells for Cardiac Cell Therapy: The Application of Cell Sheet Technology
http://dx.doi.org/10.5772/56326
473
[51] Murry, C. E, & Keller, G. (2008). Differentiation of embryonic stem cells to clinically
relevant populations: lessons from embryonic development. Cell , 132, 661-680.
[52] Yamashita, J, Itoh, H, Hirashima, M, Ogawa, M, Nishikawa, S, Yurugi, T, Naito, M,
Nakao, K, & Nishikawa, S. (2000). Flk1-positive cells derived from embryonic stem
cells serve as vascular progenitors. Nature , 408, 92-96.
[53] Yamashita, J. K, Takano, M, Hiraoka-kanie, M, Shimazu, C, Yan, P, Yanagi, K, Naka‐
no, A, Inoue, E, Kita, F, & Nishikawa, S. (2005). Prospective identification of cardiac
progenitors by a novel single cell-based cardiomyocyte induction. FASEB J , 19,
1534-1536.
[54] Laflamme, M. A, Chen, K. Y, Naumova, A. V, Muskheli, V, Fugate, J. A, Dupras, S. K,
Reinecke, H, Xu, C, Hassanipour, M, Police, S, et al. (2007). Cardiomyocytes derived
from human embryonic stem cells in pro-survival factors enhance function of infarct‐
ed rat hearts. Nat Biotechnol , 25, 1015-1024.
[55] Sone, M, Itoh, H, Yamahara, K, Yamashita, J. K, Yurugi-kobayashi, T, Nonoguchi, A,
Suzuki, Y, Chao, T. H, Sawada, N, Fukunaga, Y, et al. (2007). Pathway for differentia‐
tion of human embryonic stem cells to vascular cell components and their potential
for vascular regeneration. Arterioscler Thromb Vasc Biol , 27, 2127-2134.
[56] Van Laake, L. W, Passier, R, Monshouwer-kloots, J, Verkleij, A. J, Lips, D. J, &
Freund, C. den Ouden K, Ward-van Oostwaard D, Korving J, Tertoolen LG et al.
((2007). Human embryonic stem cell-derived cardiomyocytes survive and mature in
the mouse heart and transiently improve function after myocardial infarction. Stem
Cell Res. , 1, 9-24.
[57] Narazaki, G, Uosaki, H, Teranishi, M, Okita, K, Kim, B, Matsuoka, S, Yamanaka, S, &
Yamashita, J. K. (2008). Directed and systematic differentiation of cardiovascular cells
from mouse induced pluripotent stem cells. Circulation , 118, 498-506.
[58] Uosaki, H, Fukushima, H, Takeuchi, A, Matsuoka, S, Nakatsuji, N, Yamanaka, S, &
Yamashita, J. K. (2011). Efficient and scalable purification of cardiomyocytes from
human embryonic and induced pluripotent stem cells by VCAM1 surface expression.
PLoS One 6,e23657.
[59] Blum, B, & Benvenisty, N. (2008). The tumorigenicity of human embryonic stem cells.
Adv Cancer Res , 100, 133-158.
[60] Okita, K, Matsumura, Y, Sato, Y, Okada, A, Morizane, A, Okamoto, S, Hong, H, Na‐
kagawa, M, Tanabe, K, Tezuka, K, et al. (2011). A more efficient method to generate
integration-free human iPS cells. Nat Method , 8, 409-412.
[61] Hiratsuka, M, Uno, N, Ueda, K, Kurosaki, H, Imaoka, N, Kazuki, K, Ueno, E, Aka‐
kura, Y, Katoh, M, Osaki, M, et al. (2011). Integration-free iPS cells engineered using
human artificial chromosome vectors. PLoS One 6,e25961.
Pluripotent Stem Cells474
[62] Pelacho, B, Mazo, M, Gavira, J. J, & Prósper, F. (2011). Adult stem cells: from new cell
sources to changes in methodology. J Cardiovasc Transl Res , 4, 154-160.
[63] Müller-ehmsen, J, Whittaker, P, Kloner, R. A, Dow, J. S, Sakoda, T, Long, T. I, Laird,
P. W, & Kedes, L. (2002). Survival and development of neonatal rat cardiomyocytes
transplanted into adult myocardium. J Mol Cell Cardiol , 34, 107-116.
[64] Teng, C. J, Luo, J, Chiu, R. C, & Shum-tim, D. (2006). Massive mechanical loss of mi‐
crospheres with direct intramyocardial injection in the beating heart: implications for
cellular cardiomyoplasty. J Thorac Cardiovasc Surg , 132, 628-632.
[65] Masumoto, H, & Yamashita, J. K. Strategies in cell therapy for cardiac regeneration.
Inflammation and Regeneration. In press.
[66] Cortes-morichetti, M, Frati, G, & Schussler, O. Duong Van Huyen JP, Lauret E and
Genovese JA. ((2007). Association between a cell-seeded collagen matrix and cellular
cardiomyoplasty for myocardial support and regeneration. Tissue Eng , 13,
2681-2687.
[67] Okano, T, Yamada, N, Sakai, H, & Sakurai, Y. (1993). A novel recovery system for
cultured cells using plasma-treated polystyrene dishes grafted with poly (N-isopro‐
pylacrylamide). J Biomed Mater Res , 27, 1243-1251.
[68] Furuta, A, Miyoshi, S, Itabashi, Y, Shimizu, T, Kira, S, Hayakawa, K, Nishiyama, N,
Tanimoto, K, Hagiwara, Y, Satoh, T, et al. (2006). Pulsatile cardiac tissue grafts using
a novel three-dimensional cell sheet manipulation technique functionally integrates
with the host heart, in vivo. Circ Res , 98, 705-712.
[69] Ishii, M, Shibata, R, Numaguchi, Y, Kito, T, Suzuki, H, Shimizu, K, Ito, A, Honda, H,
& Murohara, T. (2011). Enhanced angiogenesis by transplantation of mesenchymal
stem cell sheet created by a novel magnetic tissue engineering method. Arterioscler
Thromb Vasc Biol , 31, 2210-2215.
[70] Sekine, H, Shimizu, T, Hobo, K, Sekiya, S, Yang, J, Yamato, M, Kurosawa, H, Kobaya‐
shi, E, & Okano, T. (2008). Endothelial cell coculture within tissue-engineered cardio‐
myocyte sheets enhances neovascularization and improves cardiac function of
ischemic hearts. Circulation 118,SS152., 145.
[71] Stevens, K. R, Kreutziger, K. L, Dupras, S. K, Korte, F. S, Regnier, M, Muskheli, V,
Nourse, M. B, Bendixen, K, Reinecke, H, & Murry, C. E. (2009). Physiological func‐
tion and transplantation of scaffold-free and vascularized human cardiac muscle tis‐
sue. Proc Natl Acad Sci USA , 106, 16568-16573.
Pluripotent Stem Cells for Cardiac Cell Therapy: The Application of Cell Sheet Technology
http://dx.doi.org/10.5772/56326
475

